In line with our understanding on the central role of mTOR in tumor growth, we state that mTOR targeting – here with the clinically approved drug Everolimus – is an effective und unprecedented strategy to sensitize distinct resistant cancer cell populations to a β1 integrin- and EGFR-deactivating therapy. This evidence concerns the gene EGFR and cancer.